In a phase III trial (IMpower 150) comparing carboplatin/paclitaxel/bevacizumab/atezolizumab with carboplatin/paclitaxel/bevacizumab for EGFR-mutated NSCLC patients, median OS was not reached vs. 18.7 months OS (HR 0.61), and median PFS was 10.2 vs. 6.9 months, respectively [112]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.